Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T; HAYABUSA Study Group. Kobayashi T, et al. Among authors: motoya s. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):429-437. doi: 10.1016/S2468-1253(21)00062-5. Epub 2021 Apr 20. Lancet Gastroenterol Hepatol. 2021. PMID: 33887262 Clinical Trial.
Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial.
Kita T, Ashizuka S, Ohmiya N, Yamamoto T, Kanai T, Motoya S, Hirai F, Nakase H, Moriyama T, Nakamura M, Suzuki Y, Kanmura S, Kobayashi T, Ohi H, Nozaki R, Mitsuyama K, Yamamoto S, Inatsu H, Watanabe K, Hibi T, Kitamura K. Kita T, et al. Among authors: motoya s. J Gastroenterol. 2021 Feb;56(2):147-157. doi: 10.1007/s00535-020-01741-4. Epub 2020 Nov 2. J Gastroenterol. 2021. PMID: 33140199 Free PMC article. Clinical Trial.
Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial.
Kita T, Ashizuka S, Takeda T, Matsumoto T, Ohmiya N, Nakase H, Motoya S, Ohi H, Mitsuyama K, Hisamatsu T, Kanmura S, Kato N, Ishihara S, Nakamura M, Moriyama T, Saruta M, Nozaki R, Yamamoto S, Inatsu H, Watanabe K, Kitamura K. Kita T, et al. Among authors: motoya s. J Gastroenterol Hepatol. 2022 Nov;37(11):2051-2059. doi: 10.1111/jgh.15945. Epub 2022 Jul 25. J Gastroenterol Hepatol. 2022. PMID: 35840351 Free PMC article. Clinical Trial.
Disease susceptibility genes shared by primary biliary cirrhosis and Crohn's disease in the Japanese population.
Aiba Y, Yamazaki K, Nishida N, Kawashima M, Hitomi Y, Nakamura H, Komori A, Fuyuno Y, Takahashi A, Kawaguchi T, Takazoe M, Suzuki Y, Motoya S, Matsui T, Esaki M, Matsumoto T, Kubo M, Tokunaga K, Nakamura M. Aiba Y, et al. Among authors: motoya s. J Hum Genet. 2015 Sep;60(9):525-31. doi: 10.1038/jhg.2015.59. Epub 2015 Jun 18. J Hum Genet. 2015. PMID: 26084578
Association study of 71 European Crohn's disease susceptibility loci in a Japanese population.
Hirano A, Yamazaki K, Umeno J, Ashikawa K, Aoki M, Matsumoto T, Nakamura S, Ninomiya T, Matsui T, Hirai F, Kawaguchi T, Takazoe M, Tanaka H, Motoya S, Kiyohara Y, Kitazono T, Nakamura Y, Kamatani N, Kubo M. Hirano A, et al. Among authors: motoya s. Inflamm Bowel Dis. 2013 Mar;19(3):526-33. doi: 10.1097/MIB.0b013e31828075e7. Inflamm Bowel Dis. 2013. PMID: 23388546
114 results